Literature DB >> 12001115

pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.

John C Cheville1, Horst Zincke, Christine M Lohse, Thomas J Sebo, Darren Riehle, Amy L Weaver, Michael L Blute.   

Abstract

BACKGROUND: The majority of patients with pT1 clear cell renal cell carcinoma (RCC) are cured with nephrectomy. However, a few patients will die of RCC. In several studies, MIB-1 proliferative activity was identified as an independent predictor of survival in patients with RCC. The objective of the current study was to examine MIB-1 proliferative activity in a large series of patients with pT1 clear cell RCC who were treated uniformly with radical nephrectomy, and to examine the association between proliferative activity and cancer specific survival in a multivariate model incorporating tumor size, nuclear grade, and tumor necrosis.
METHODS: Patients with solitary pT1 clear cell RCC who underwent radical nephrectomy between 1970-1997 were eligible for the current study. For each of the 40 patients who died of RCC, a stratified random sample of at least 3 year-matched patients who still were alive or had died of other causes at the time of last follow-up was selected. Patient age at nephrectomy, patient gender, tumor size, nuclear grade, and tumor necrosis were evaluated, and the MIB-1 proliferative activity was assessed using digital image analysis. Univariate and multivariate Cox proportional hazards models were fit to assess the features associated with cancer specific survival. The associations between MIB-1 proliferative activity and pathologic features were assessed using the Wilcoxon rank sum test.
RESULTS: The mean MIB-1 value for those patients who died of clear cell RCC was 6.5% compared with 3.6% for those patients who died of other causes or were still alive at the time of last follow-up. Patients whose tumor had an MIB-1 proliferative activity > o r = 5.0% were more than twice as likely to die of RCC than patients whose tumors had a MIB-1 activity < 5% (P = 0.02). However, after adjusting for tumor size, nuclear grade, and necrosis, MIB-1 proliferative activity was not found to be associated significantly with cancer specific survival. There was a significant association between MIB-1 proliferative activity and tumor size, nuclear grade, and necrosis.
CONCLUSIONS: After adjusting for tumor size, nuclear grade, and necrosis, MIB-1 proliferative activity was not found to be an independent predictor of outcome in patients with pT1 clear cell RCC who were treated with radical nephrectomy. There was a significant association between MIB-1 and other well established pathologic prognostic features of pT1 clear cell RCC. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12001115     DOI: 10.1002/cncr.10433

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Classical pathology versus molecular pathology in renal cell carcinoma.

Authors:  Peggy Soung Sullivan; JianYu Rao; Liang Cheng; Richard J Cote
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

Review 2.  Best Practice No 180. Nephrectomy for renal tumour; dissection guide and dataset.

Authors:  S Fleming; D F R Griffiths
Journal:  J Clin Pathol       Date:  2005-01       Impact factor: 3.411

Review 3.  Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Yongpeng Xie; Luyao Chen; Xin Ma; Hongzhao Li; Liangyou Gu; Yu Gao; Yang Fan; Yu Zhang; Xu Zhang
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

4.  Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome.

Authors:  Alexander Laird; Fiach C O'Mahony; Jyoti Nanda; Antony C P Riddick; Marie O'Donnell; David J Harrison; Grant D Stewart
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

5.  Stage-dependent prognostic impact of molecular signatures in clear cell renal cell carcinoma.

Authors:  Thomas Weber; Matthias Meinhardt; Stefan Zastrow; Andreas Wienke; Kati Erdmann; Jörg Hofmann; Susanne Fuessel; Manfred P Wirth
Journal:  Onco Targets Ther       Date:  2014-05-02       Impact factor: 4.147

6.  Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals.

Authors:  Zhun Wang; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Cancer Manag Res       Date:  2017-11-21       Impact factor: 3.989

7.  The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.

Authors:  Damien Ambrosetti; Maeva Dufies; Bérengère Dadone; Matthieu Durand; Delphine Borchiellini; Jean Amiel; Jacques Pouyssegur; Nathalie Rioux-Leclercq; Gilles Pages; Fanny Burel-Vandenbos; Nathalie M Mazure
Journal:  PLoS One       Date:  2018-02-26       Impact factor: 3.240

8.  Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.

Authors:  Tian Zhang; Sarabjot Pabla; Felicia L Lenzo; Jeffrey M Conroy; Mary K Nesline; Sean T Glenn; Antonios Papanicolau-Sengos; Blake Burgher; Vincent Giamo; Jonathan Andreas; Yirong Wang; Wiam Bshara; Katherine G Madden; Keisuke Shirai; Konstantin Dragnev; Laura J Tafe; Rajan Gupta; Jason Zhu; Matthew Labriola; Shannon McCall; Daniel J George; Pooja Ghatalia; Farshid Dayyani; Robert Edwards; Michelle S Park; Rajbir Singh; Robin Jacob; Saby George; Bo Xu; Matthew Zibelman; Razelle Kurzrock; Carl Morrison
Journal:  Oncoimmunology       Date:  2020-06-10       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.